HER2 low breast carcinoma
Clinical trials for HER2 low breast carcinoma explained in plain language.
Never miss a new study
Get alerted when new HER2 low breast carcinoma trials appear
Sign up with your email to follow new studies for HER2 low breast carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new drug make hormone therapy work better for breast cancer?
Disease control Recruiting nowThis trial tests whether adding an experimental drug called culmerciclib to standard hormone therapy can shrink tumors more effectively in women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. Participants receive either the combination or hormone therap…
Matched conditions: HER2 LOW BREAST CARCINOMA
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a new drug combo outsmart breast cancer that resists current therapy?
Disease control Recruiting nowThis trial tests whether an experimental drug called HER3-DXd, given alone or with olaparib, can safely shrink tumors in people with advanced breast cancer that has progressed after treatment with T-DXd. The study includes two groups: one receiving the combination, the other rece…
Matched conditions: HER2 LOW BREAST CARCINOMA
Phase 1/2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a platform trial match the right drug combo to each tumor?
Disease control Recruiting nowThis phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…
Matched conditions: HER2 LOW BREAST CARCINOMA
Phase 1/2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New Antibody-Drug combo shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThis phase II trial is testing a drug called ARX788 in 36 people with HER2-low breast cancer that has spread or cannot be removed. ARX788 is an antibody-drug conjugate that delivers a toxin directly to cancer cells with the HER2 protein. The main goal is to see how many patients'…
Matched conditions: HER2 LOW BREAST CARCINOMA
Phase 2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug duo aims to outsmart resistant breast cancer
Disease control Recruiting nowThis study tests a combination of two drugs—elacestrant and trastuzumab deruxtecan—in people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultralow) that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The goal is to find the s…
Matched conditions: HER2 LOW BREAST CARCINOMA
Phase 1/2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC